These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 31205491)

  • 1. Neurochemical markers in CSF of adolescent and adult SMA patients undergoing nusinersen treatment.
    Wurster CD; Günther R; Steinacker P; Dreyhaupt J; Wollinsky K; Uzelac Z; Witzel S; Kocak T; Winter B; Koch JC; Lingor P; Petri S; Ludolph AC; Hermann A; Otto M
    Ther Adv Neurol Disord; 2019; 12():1756286419846058. PubMed ID: 31205491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurofilament light chain in serum of adolescent and adult SMA patients under treatment with nusinersen.
    Wurster CD; Steinacker P; Günther R; Koch JC; Lingor P; Uzelac Z; Witzel S; Wollinsky K; Winter B; Osmanovic A; Schreiber-Katz O; Al Shweiki R; Ludolph AC; Petri S; Hermann A; Otto M;
    J Neurol; 2020 Jan; 267(1):36-44. PubMed ID: 31552549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurofilament Levels in CSF and Serum in an Adult SMA Cohort Treated with Nusinersen.
    Rich KA; Fox A; Yalvac M; Heintzman S; Tellez M; Bartlett A; Severyn S; Linsenmayer M; Kelly K; Reynolds J; Sterling GB; Weaver T; Rajneesh K; Pino MG; Arnold WD; Elsheikh B; Kolb SJ
    J Neuromuscul Dis; 2022; 9(1):111-119. PubMed ID: 34776417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal Fluid and Clinical Profiles in Adult Type 2-3 Spinal Muscular Atrophy Patients Treated with Nusinersen: An 18-Month Single-Centre Experience.
    Milella G; Introna A; D'Errico E; Fraddosio A; Scaglione G; Morea A; Ucci M; Ruggieri M; Mastrapasqua M; Megna M; Puntillo F; Simone IL
    Clin Drug Investig; 2021 Sep; 41(9):775-784. PubMed ID: 34389971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nusinersen treatment and cerebrospinal fluid neurofilaments: An explorative study on Spinal Muscular Atrophy type 3 patients.
    Faravelli I; Meneri M; Saccomanno D; Velardo D; Abati E; Gagliardi D; Parente V; Petrozzi L; Ronchi D; Stocchetti N; Calderini E; D'Angelo G; Chidini G; Prandi E; Ricci G; Siciliano G; Bresolin N; Comi GP; Corti S; Magri F; Govoni A
    J Cell Mol Med; 2020 Mar; 24(5):3034-3039. PubMed ID: 32032473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Routine Cerebrospinal Fluid (CSF) Parameters in Patients With Spinal Muscular Atrophy (SMA) Treated With Nusinersen.
    Wurster CD; Koch JC; Cordts I; Dreyhaupt J; Otto M; Uzelac Z; Witzel S; Winter B; Kocak T; Schocke M; Weydt P; Wollinsky K; Ludolph AC; Deschauer M; Lingor P; Tumani H; Hermann A; Günther R
    Front Neurol; 2019; 10():1179. PubMed ID: 31787927
    [No Abstract]   [Full Text] [Related]  

  • 7. Safety and Treatment Effects of Nusinersen in Longstanding Adult 5q-SMA Type 3 - A Prospective Observational Study.
    Walter MC; Wenninger S; Thiele S; Stauber J; Hiebeler M; Greckl E; Stahl K; Pechmann A; Lochmüller H; Kirschner J; Schoser B
    J Neuromuscul Dis; 2019; 6(4):453-465. PubMed ID: 31594243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal fluid proteomic profiling in nusinersen-treated patients with spinal muscular atrophy.
    Kessler T; Latzer P; Schmid D; Warnken U; Saffari A; Ziegler A; Kollmer J; Möhlenbruch M; Ulfert C; Herweh C; Wildemann B; Wick W; Weiler M
    J Neurochem; 2020 Jun; 153(5):650-661. PubMed ID: 31903607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphorylated neurofilament heavy chain in cerebrospinal fluid and plasma as a Nusinersen treatment response marker in childhood-onset SMA individuals from Serbia.
    Brkušanin M; Kosać A; Branković-Srećković V; Jovanović K; Perić S; Karanović J; Matijašević Joković S; Garai N; Pešović J; Nikolić D; Stević Z; Brajušković G; Milić-Rašić V; Savić-Pavićević D
    Front Neurol; 2024; 15():1394001. PubMed ID: 38756215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurofilament Heavy Chain and Tau Protein Are Not Elevated in Cerebrospinal Fluid of Adult Patients with Spinal Muscular Atrophy during Loading with Nusinersen.
    Totzeck A; Stolte B; Kizina K; Bolz S; Schlag M; Thimm A; Kleinschnitz C; Hagenacker T
    Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31671515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Muscle microRNAs in the cerebrospinal fluid predict clinical response to nusinersen therapy in type II and type III spinal muscular atrophy patients.
    Magen I; Aharoni S; Yacovzada NS; Tokatly Latzer I; Alves CRR; Sagi L; Fattal-Valevski A; Swoboda KJ; Katz J; Bruckheimer E; Nevo Y; Hornstein E
    Eur J Neurol; 2022 Aug; 29(8):2420-2430. PubMed ID: 35510740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biochemical and clinical biomarkers in adult SMA 3-4 patients treated with nusinersen for 22 months.
    De Wel B; De Schaepdryver M; Poesen K; Claeys KG
    Ann Clin Transl Neurol; 2022 Aug; 9(8):1241-1251. PubMed ID: 35833245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy.
    Chiriboga CA; Swoboda KJ; Darras BT; Iannaccone ST; Montes J; De Vivo DC; Norris DA; Bennett CF; Bishop KM
    Neurology; 2016 Mar; 86(10):890-7. PubMed ID: 26865511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of neurofilament light and heavy chain in spinal muscular atrophy and amyotrophic lateral sclerosis: A pilot study.
    Li JY; Dai Y; Sun XH; Ren HT; Shen DC; Yang XZ; Liu MS; Cui LY
    Brain Behav; 2023 May; 13(5):e2997. PubMed ID: 37070132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Feasibility and safety of intrathecal treatment with nusinersen in adult patients with spinal muscular atrophy.
    Stolte B; Totzeck A; Kizina K; Bolz S; Pietruck L; Mönninghoff C; Guberina N; Oldenburg D; Forsting M; Kleinschnitz C; Hagenacker T
    Ther Adv Neurol Disord; 2018; 11():1756286418803246. PubMed ID: 30305849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NFL is a marker of treatment response in children with SMA treated with nusinersen.
    Olsson B; Alberg L; Cullen NC; Michael E; Wahlgren L; Kroksmark AK; Rostasy K; Blennow K; Zetterberg H; Tulinius M
    J Neurol; 2019 Sep; 266(9):2129-2136. PubMed ID: 31123861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of putative CSF biomarkers in paediatric spinal muscular atrophy (SMA) patients before and during treatment with nusinersen.
    Johannsen J; Weiss D; Daubmann A; Schmitz L; Denecke J
    J Cell Mol Med; 2021 Sep; 25(17):8419-8431. PubMed ID: 34312963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebrospinal Fluid Parameters in Antisense Oligonucleotide-Treated Adult 5q-Spinal Muscular Atrophy Patients.
    Müschen LH; Osmanovic A; Binz C; Jendretzky KF; Ranxha G; Bronzlik P; Abu-Fares O; Wiehler F; Möhn N; Hümmert MW; Gingele S; Götz F; Stangel M; Skripuletz T; Schreiber-Katz O; Petri S
    Brain Sci; 2021 Feb; 11(3):. PubMed ID: 33652830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug treatment for spinal muscular atrophy types II and III.
    Wadman RI; van der Pol WL; Bosboom WM; Asselman FL; van den Berg LH; Iannaccone ST; Vrancken AF
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD006282. PubMed ID: 32006461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy.
    Mercuri E; Darras BT; Chiriboga CA; Day JW; Campbell C; Connolly AM; Iannaccone ST; Kirschner J; Kuntz NL; Saito K; Shieh PB; Tulinius M; Mazzone ES; Montes J; Bishop KM; Yang Q; Foster R; Gheuens S; Bennett CF; Farwell W; Schneider E; De Vivo DC; Finkel RS;
    N Engl J Med; 2018 Feb; 378(7):625-635. PubMed ID: 29443664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.